mRNA Profiling for Body Fluid Identification

Every nucleated human cell contains roughly the same three billion base pairs of DNA. What makes a prostate epithelial cell different from a buccal epithelial cell is not its genome but its transcriptome: the particular subset of genes it is currently expressing. Differentiated tissues maintain characteristic gene-expression signatures because transcription factors lock certain promoters open and others closed in a tissue-specific way. Those signatures are stable enough across individuals to serve as reliable fluid markers.

The practical requirement for a forensic mRNA marker is strict. A target gene must be expressed at high levels in one fluid and at undetectable or very low levels in all other forensically common fluids, including peripheral blood, semen, saliva, menstrual blood, vaginal fluid, and skin. It must also be detectable in the small amounts of RNA that survive in a dried, aged stain. And it must not produce false positives from common environmental contaminants such as bacteria or plant material.

Research groups in Europe, North America, and Asia have independently validated panels of mRNA markers over the past two decades. The targets below represent the current consensus from peer-reviewed validation studies, though laboratories sometimes add or substitute markers based on their own performance data.

A key practical point: no single marker is perfectly specific. PRM1 is excellent for semen but can yield trace signal from shed skin cells in rare cases. STATH is salivary, but traces appear in nasal mucus. This is why validated assays test a panel of two to four markers per fluid rather than relying on a single target, and why a positive call requires concordant results across the panel.

Reverse transcription PCR is the dominant platform for forensic mRNA work because it is sensitive, flexible, and already familiar to forensic DNA laboratories. The workflow has two phases: RNA is first converted to a stable complementary DNA (cDNA) copy by reverse transcriptase, then the cDNA is amplified and detected using the same thermal cyclers used for STR typing.

1. RNA extraction
   The stain is extracted using a chaotropic lysis buffer (guanidinium thiocyanate-based) or a silica-column kit optimised for RNA. Co-extraction of DNA is common, which allows a single extract to yield both fluid identification data (mRNA) and contributor identity (STR).
2. Reverse transcription
   Reverse transcriptase converts the RNA template into cDNA using either random hexamers or gene-specific primers. This step must be carried out promptly and on ice to prevent RNA degradation by RNases.
3. PCR amplification and detection
   Target cDNA sequences are amplified. In qualitative assays, end-point PCR followed by capillary electrophoresis distinguishes transcript size from genomic DNA (intron-spanning primers produce a size shift). In quantitative assays (RT-qPCR), a fluorescent probe (TaqMan) or intercalating dye tracks amplification in real time.
4. Interpretation
   A sample is called positive for a fluid when the expected marker transcripts are detected above threshold in the absence of inhibition controls. A multiplex panel reports each target simultaneously, and concordance across the panel supports a positive fluid call.

NanoString's nCounter platform counts individual RNA molecules by hybridising them to pairs of fluorescent barcoded probes, then immobilising and imaging the resulting complexes. There is no amplification step. This matters for forensic samples in two ways: PCR bias does not accumulate, so low-abundance transcripts are not swamped by high-abundance ones, and the digital read-out is inherently quantitative without the calibration overhead of RT-qPCR.

A forensic mRNA panel published by Sijen and colleagues at the Netherlands Forensic Institute used nCounter to profile 16 mRNA markers across the five fluids from aged and degraded stains. The platform distinguished fluid types from stains up to six years old stored at room temperature, a stability range that exceeds typical RT-PCR performance on the same samples, because the absence of PCR does not require the RNA template to serve as a primer-binding substrate.

For routine casework, RT-qPCR remains the default because laboratories already own the instruments. NanoString is most attractive for validation studies, where characterising many targets simultaneously across a large reference sample set saves time, and for complex mixture scenarios where a wide panel helps resolve which fluids are present.

The perception that RNA is inherently unstable comes from experience with liquid samples and from the sensitivity of fresh tissue to freeze-thaw cycles. In a dried stain, the situation is different. Desiccation slows enzymatic degradation dramatically, and the protein matrix of a stain can encapsulate and protect RNA molecules from RNases in the environment.

A series of deliberate stability studies has tested mRNA markers in blood, semen, and saliva stains stored under controlled conditions. Under cool, dry, dark conditions (4 degrees Celsius, low humidity, no UV), semen mRNA targets have been detected in stains aged five to seven years. Blood RNA markers are detectable in stains aged one to two years under similar conditions. Saliva fares worst: the high RNase content from oral bacteria degrades RNA rapidly, and saliva stains left at room temperature often lose detectable mRNA within days to weeks.

• Temperature: high temperatures accelerate degradation. Stains stored at 37 degrees show rapid RNA loss versus stains stored at 4 degrees.
• Humidity: moisture reactivates RNase activity and promotes bacterial growth. Wet or humid conditions destroy RNA faster than dry ones regardless of temperature.
• UV exposure: ultraviolet light causes RNA strand breaks. Outdoor stains exposed to direct sunlight degrade far more rapidly than stains recovered from indoor surfaces.
• Substrate: porous substrates like cotton bind and stabilise RNA. Non-porous surfaces such as glass or tile do not protect RNA from environmental exposure.

SWGMAT (Scientific Working Group for Materials Analysis) produced early guidance on the validation of forensic body-fluid identification assays, including specificity panels, sensitivity limits, interference studies, and mixture characterisation. OSAC, formed under NIST in 2014 to modernise US forensic standards, built on and formalised those requirements.

For an mRNA assay to be considered validated under OSAC guidance, a laboratory must document the following:

1. Specificity: the assay must be tested against all other forensically relevant body fluids (minimum: peripheral blood, semen, saliva, menstrual blood, vaginal fluid, skin cells) and must not produce false-positive calls for any of them.
2. Sensitivity: the minimum stain area or RNA input at which the assay reliably calls the correct fluid must be determined. Typical performance benchmarks are detection from 0.1 to 1 cm2 of fresh dried stain.
3. Stability: stains aged under realistic forensic storage conditions should be included in validation to establish the range of conditions under which the assay is valid.
4. Mixture studies: two-fluid and three-fluid mixtures at known ratios must be characterised to establish which minor-component detection limits apply.
5. Interference: common substrates (denim, cotton, nylon), surface contaminants (household cleaners, lubricants), and co-deposited biological materials must be tested for inhibitory or confounding effects.

Internationally, ISO 17025 accreditation requires laboratories to validate methods before use and to participate in proficiency testing. In jurisdictions outside the United States, national-level guidelines (for instance from the European Network of Forensic Science Institutes, ENFSI) follow similar principles to OSAC but with different documentation formats. The science is international; the compliance paperwork is local.